The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from stealth with $30m.

The mental healthcare app developer boosted its overall funding to $120m in a round that included Cigna Ventures and Kaiser Permanente Ventures.

Cigna and Kaiser Permanente have participated in a $50m series D round for Ginger, bringing the MIT spinout's total funding to more than $120m.

UCL's Freeline Therapeutics has priced its shares at $18 to raise nearly $159m through an IPO on the Nasdaq Global Select Market.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Humana-backed primary care network Oak Street Health is raising $328m in an offering in which it priced its shares above an expanded range.

Novartis Venture Fund has helped seed a T-cell drug developer founded from Seattle Children's Hospital, Benaroya Research Institute and MIGAL Galilee.

Lepu Medical's immuno-oncology spinoff secured $186m in a round co-led by Ping An Capital and the Sunshine Insurance-backed Riverhead Capital.

The T-cell drug developer has launched with $20m from a seed round co-led by corporate venturing unit Novartis Venture Fund.

NetScientific is poised to acquire EMV Capital in an all-share deal after appointing the latter's managing director as its chief executive in May.